CN Stock MarketDetailed Quotes

688513 Chengdu Easton Biopharmaceuticals

Watchlist
  • 29.66
  • -0.03-0.10%
Market Closed Jan 3 15:00 CST
5.24BMarket Cap20.95P/E (TTM)

Chengdu Easton Biopharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Assets
Current assets
Money funds
9.28%585.01M
6.56%682.62M
32.74%823.67M
-5.99%781.23M
-4.38%535.35M
47.17%640.57M
3.97%620.51M
-20.91%830.97M
166.11%559.86M
49.04%435.27M
Transactional financial assets
-6.39%824.18M
17.05%851.13M
-10.35%663.97M
43.66%741.78M
14.93%880.46M
-17.30%727.13M
-9.16%740.65M
13.78%516.36M
-44.26%766.08M
-29.94%879.19M
Notes receivable and accounts receivable
66.80%250.94M
91.04%228.64M
18.97%174.14M
-6.14%134.27M
4.70%150.45M
8.76%119.68M
48.65%146.37M
20.55%143.06M
13.54%143.7M
-13.50%110.04M
-Notes receivable
114.46%17.9M
-8.73%7.14M
38.26%12.78M
130.29%14.09M
35.80%8.35M
-14.09%7.83M
129.99%9.24M
-2.09%6.12M
132.39%6.15M
75.08%9.11M
-Accounts receivable
64.00%233.04M
98.02%221.49M
17.67%161.36M
-12.24%120.18M
3.31%142.1M
10.83%111.86M
45.19%137.13M
21.80%136.94M
11.00%137.55M
-17.28%100.93M
Other receivables (including interest and dividends)
11.98%705.01K
505.40%2.59M
38.10%1.2M
-47.18%659.83K
-74.35%629.6K
10.32%427.38K
101.19%872.19K
630.83%1.25M
671.58%2.45M
-12.26%387.41K
-Other receivable
----
505.40%2.59M
----
-47.18%659.83K
----
10.32%427.38K
----
630.83%1.25M
----
-12.26%387.41K
Advance payment
34.41%19.13M
10.03%19.56M
-0.90%15.9M
-44.81%8.78M
42.14%14.23M
5.52%17.77M
-7.49%16.04M
-11.48%15.91M
-19.11%10.01M
43.85%16.84M
Inventories
13.91%184.33M
12.69%183.47M
11.92%174.53M
14.28%160.98M
30.72%161.81M
29.13%162.8M
28.72%155.94M
35.86%140.87M
37.76%123.78M
40.41%126.08M
Receivable financing
89.68%70.8M
127.55%60.64M
10.72%41.37M
14.72%43.43M
-0.44%37.32M
-10.25%26.65M
141.44%37.36M
370.37%37.86M
113.30%37.49M
105.42%29.69M
Other current assets
-17.40%5.21M
112.23%11.13M
-64.48%8.9M
-48.64%11.73M
-70.21%6.3M
-73.37%5.24M
3.97%25.06M
-12.07%22.84M
4.75%21.16M
-4.26%19.69M
Total current assets
8.61%1.94B
19.97%2.04B
9.23%1.9B
10.17%1.88B
7.33%1.79B
5.14%1.7B
3.18%1.74B
-3.93%1.71B
-10.11%1.66B
-10.70%1.62B
Non Current assets
Other equity investment
0.00%10M
--10M
--10M
--10M
--10M
----
----
----
----
----
Other non-current financial assets
3.23%48M
24.68%48M
24.68%48M
111.36%46.5M
111.36%46.5M
75.00%38.5M
102.63%38.5M
--22M
--22M
--22M
Fixed assets
----
8.35%1.03B
----
17.46%1.07B
----
27.62%950.5M
----
284.37%909.85M
----
256.46%744.79M
Constru in process
----
-8.61%219.98M
----
-19.42%186.19M
----
-8.71%240.7M
----
-63.76%231.06M
----
-45.97%263.68M
Construction materials
----
----
----
22.99%64.25K
----
--63.19K
----
-79.73%52.24K
----
----
Intangible assets
-2.84%33.39M
-2.42%33.81M
-1.89%34.27M
-0.43%34.46M
3.03%34.37M
2.08%34.65M
1.80%34.93M
2.67%34.61M
-0.76%33.36M
0.43%33.94M
Development expenditure
48.50%68.21M
40.46%63.38M
35.06%58.95M
17.92%50M
28.87%45.93M
76.33%45.13M
170.24%43.65M
426.87%42.4M
--35.64M
--25.59M
Long deferred expense
-32.34%3.7M
72.21%4.07M
68.63%4.44M
66.25%4.92M
65.95%5.47M
-34.86%2.36M
-33.59%2.63M
-31.14%2.96M
-22.95%3.29M
-15.98%3.62M
Deferred tax assets
82.38%11.95M
44.44%9.44M
19.95%8.25M
-1.84%8.57M
-18.71%6.55M
-31.38%6.53M
-36.22%6.88M
-28.18%8.73M
-23.88%8.06M
9.45%9.52M
Other non current assets
-37.91%24.4M
-22.82%32.45M
-36.07%26.3M
-6.87%29.89M
0.78%39.29M
-61.56%42.04M
-64.20%41.14M
-49.37%32.09M
25.17%38.99M
325.00%109.37M
Total non current assets
3.39%1.48B
6.44%1.47B
8.46%1.47B
11.88%1.46B
6.76%1.43B
7.71%1.39B
15.63%1.36B
31.34%1.31B
50.69%1.34B
67.12%1.29B
Total assets
6.29%3.42B
13.89%3.51B
8.89%3.37B
10.91%3.35B
7.08%3.22B
6.28%3.09B
8.28%3.1B
8.73%3.02B
9.60%3B
12.50%2.9B
Liabilities
Current liabilities
Short term loan
-3.97%125.89M
60.45%210.32M
29.23%161.09M
71.85%180.95M
-7.03%131.1M
8.92%131.08M
149.05%124.65M
425.87%105.29M
--141.01M
--120.34M
Notes payable and accounts payable
4.18%163.73M
11.29%188.48M
5.26%174.9M
15.35%180.94M
-9.27%157.16M
-7.02%169.36M
-20.66%166.16M
-23.08%156.86M
-21.93%173.22M
16.88%182.14M
-Notes payable
6.54%39.8M
-12.39%46.58M
1.03%43.68M
398.21%45.8M
19.20%37.35M
85.70%53.17M
8.71%43.24M
-79.99%9.19M
-39.83%31.34M
-29.20%28.63M
-Accounts payable
3.45%123.94M
22.12%141.9M
6.75%131.21M
-8.48%135.14M
-15.56%119.81M
-24.31%116.19M
-27.55%122.92M
-6.52%147.67M
-16.44%141.88M
33.03%153.51M
Contract liabilities
27.51%36.21M
96.50%35.02M
111.24%44.22M
11.40%31.98M
15.63%28.4M
-1.77%17.82M
29.22%20.93M
161.15%28.71M
132.65%24.56M
128.34%18.15M
Salaries payable
1.80%38.22M
-8.69%32.34M
-34.80%26.72M
-9.92%49.97M
-17.68%37.54M
3.26%35.42M
46.65%40.99M
26.70%55.47M
4.39%45.61M
18.69%34.3M
Taxs payable
56.03%34.89M
87.14%31.34M
63.12%22.71M
7.86%15.87M
-0.16%22.36M
-15.00%16.74M
-15.58%13.92M
-12.28%14.71M
1.65%22.4M
22.82%19.7M
Other payable (including interest and dividends)
39.57%247.15M
63.23%262.46M
29.95%225.84M
21.20%195.94M
15.50%177.08M
14.55%160.79M
22.72%173.8M
22.83%161.67M
9.38%153.31M
2.67%140.37M
-Dividend payable
----
--29.63M
----
----
----
----
----
----
----
----
-Other payable
----
44.81%232.83M
----
21.20%195.94M
----
14.55%160.79M
----
22.83%161.67M
----
2.67%140.37M
Non current liabilities due within one year
--2.93M
--2.93M
--2.93M
--2.93M
----
----
----
----
----
----
Other current liabilities
228.27%13.55M
81.13%4.64M
45.05%8.25M
-62.31%2.51M
6.64%4.13M
-57.03%2.56M
81.46%5.69M
24.67%6.67M
29.34%3.87M
-3.96%5.96M
Total current liabilities
18.79%662.57M
43.79%767.53M
22.07%666.67M
24.88%661.09M
-1.10%557.77M
2.46%533.77M
17.48%546.13M
22.41%529.39M
27.79%563.97M
48.15%520.96M
Current liabilities
Deferred tax liabilities
42.11%2.62M
93.15%2.41M
74.83%1.79M
65.06%1.46M
32.95%1.84M
-12.12%1.25M
46.83%1.02M
665.62%882.64K
41.99%1.39M
19.85%1.42M
Long term deferred income
-6.91%37.85M
-4.44%39M
-12.33%40.16M
-3.80%41.18M
-8.78%40.66M
-13.80%40.81M
-9.09%45.82M
-16.10%42.81M
-13.61%44.57M
-6.01%47.34M
Total non current liabilities
-9.14%78.63M
89.13%79.54M
74.19%81.59M
88.22%82.24M
88.28%86.54M
-13.75%42.05M
-8.33%46.84M
-14.57%43.69M
-12.57%45.96M
-5.41%48.76M
Total liabilities
15.04%741.2M
47.10%847.07M
26.19%748.26M
29.71%743.33M
5.64%644.31M
1.07%575.82M
14.93%592.97M
18.50%573.08M
23.50%609.93M
41.30%569.71M
Shareholders equity
Paid-in capital
47.00%176.53M
47.00%176.53M
0.00%120.09M
0.00%120.09M
0.00%120.09M
0.00%120.09M
0.00%120.09M
0.00%120.09M
0.00%120.09M
0.00%120.09M
Capital reserve funds
-4.39%1.38B
-4.98%1.37B
0.02%1.44B
0.02%1.44B
0.00%1.44B
0.00%1.44B
0.00%1.44B
0.00%1.44B
0.00%1.44B
0.00%1.44B
Surplus reserve funds
0.00%60.05M
0.00%60.05M
0.00%60.05M
0.00%60.05M
0.00%60.05M
0.00%60.05M
0.00%60.05M
0.00%60.05M
32.25%60.05M
32.25%60.05M
Retained profit
19.04%1.13B
19.43%1.06B
19.67%1.05B
19.42%979.58M
23.07%946.72M
24.87%884.53M
22.19%881.25M
22.90%820.26M
21.01%769.23M
24.94%708.37M
Less:Treasury stock
13,104.68%69.45M
--4.58K
--54.31M
--1.59M
--525.95K
----
----
----
----
----
Specific reserves
74.13%2.23M
113.35%1.92M
281.54%1.39M
5,799.71%989.86K
939.12%1.28M
-4.00%898.71K
-18.03%363.5K
-76.81%16.78K
-89.37%123.45K
9.69%936.14K
Shareholders equity without minority interests
4.10%2.68B
6.27%2.67B
4.80%2.63B
6.50%2.6B
7.44%2.57B
7.55%2.51B
6.82%2.51B
6.67%2.44B
6.55%2.39B
7.17%2.33B
Total shareholder equity
4.10%2.68B
6.27%2.67B
4.80%2.63B
6.50%2.6B
7.44%2.57B
7.55%2.51B
6.82%2.51B
6.67%2.44B
6.55%2.39B
7.17%2.33B
Total liabilityies and equity
6.29%3.42B
13.89%3.51B
8.89%3.37B
10.91%3.35B
7.08%3.22B
6.28%3.09B
8.28%3.1B
8.73%3.02B
9.60%3B
12.50%2.9B
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
--
Auditor
--
--
--
Zhonghui Certified Public Accountants (Special General Partnership)
--
--
--
Zhonghui Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024 (Q6)Jun 30, 2024 (Q3)Mar 31, 2024 (FY)Dec 31, 2023 (Q9)Sep 30, 2023 (Q6)Jun 30, 2023 (Q3)Mar 31, 2023 (FY)Dec 31, 2022 (Q9)Sep 30, 2022 (Q6)Jun 30, 2022
Assets
Current assets
Money funds 9.28%585.01M 6.56%682.62M 32.74%823.67M -5.99%781.23M -4.38%535.35M 47.17%640.57M 3.97%620.51M -20.91%830.97M 166.11%559.86M 49.04%435.27M
Transactional financial assets -6.39%824.18M 17.05%851.13M -10.35%663.97M 43.66%741.78M 14.93%880.46M -17.30%727.13M -9.16%740.65M 13.78%516.36M -44.26%766.08M -29.94%879.19M
Notes receivable and accounts receivable 66.80%250.94M 91.04%228.64M 18.97%174.14M -6.14%134.27M 4.70%150.45M 8.76%119.68M 48.65%146.37M 20.55%143.06M 13.54%143.7M -13.50%110.04M
-Notes receivable 114.46%17.9M -8.73%7.14M 38.26%12.78M 130.29%14.09M 35.80%8.35M -14.09%7.83M 129.99%9.24M -2.09%6.12M 132.39%6.15M 75.08%9.11M
-Accounts receivable 64.00%233.04M 98.02%221.49M 17.67%161.36M -12.24%120.18M 3.31%142.1M 10.83%111.86M 45.19%137.13M 21.80%136.94M 11.00%137.55M -17.28%100.93M
Other receivables (including interest and dividends) 11.98%705.01K 505.40%2.59M 38.10%1.2M -47.18%659.83K -74.35%629.6K 10.32%427.38K 101.19%872.19K 630.83%1.25M 671.58%2.45M -12.26%387.41K
-Other receivable ---- 505.40%2.59M ---- -47.18%659.83K ---- 10.32%427.38K ---- 630.83%1.25M ---- -12.26%387.41K
Advance payment 34.41%19.13M 10.03%19.56M -0.90%15.9M -44.81%8.78M 42.14%14.23M 5.52%17.77M -7.49%16.04M -11.48%15.91M -19.11%10.01M 43.85%16.84M
Inventories 13.91%184.33M 12.69%183.47M 11.92%174.53M 14.28%160.98M 30.72%161.81M 29.13%162.8M 28.72%155.94M 35.86%140.87M 37.76%123.78M 40.41%126.08M
Receivable financing 89.68%70.8M 127.55%60.64M 10.72%41.37M 14.72%43.43M -0.44%37.32M -10.25%26.65M 141.44%37.36M 370.37%37.86M 113.30%37.49M 105.42%29.69M
Other current assets -17.40%5.21M 112.23%11.13M -64.48%8.9M -48.64%11.73M -70.21%6.3M -73.37%5.24M 3.97%25.06M -12.07%22.84M 4.75%21.16M -4.26%19.69M
Total current assets 8.61%1.94B 19.97%2.04B 9.23%1.9B 10.17%1.88B 7.33%1.79B 5.14%1.7B 3.18%1.74B -3.93%1.71B -10.11%1.66B -10.70%1.62B
Non Current assets
Other equity investment 0.00%10M --10M --10M --10M --10M ---- ---- ---- ---- ----
Other non-current financial assets 3.23%48M 24.68%48M 24.68%48M 111.36%46.5M 111.36%46.5M 75.00%38.5M 102.63%38.5M --22M --22M --22M
Fixed assets ---- 8.35%1.03B ---- 17.46%1.07B ---- 27.62%950.5M ---- 284.37%909.85M ---- 256.46%744.79M
Constru in process ---- -8.61%219.98M ---- -19.42%186.19M ---- -8.71%240.7M ---- -63.76%231.06M ---- -45.97%263.68M
Construction materials ---- ---- ---- 22.99%64.25K ---- --63.19K ---- -79.73%52.24K ---- ----
Intangible assets -2.84%33.39M -2.42%33.81M -1.89%34.27M -0.43%34.46M 3.03%34.37M 2.08%34.65M 1.80%34.93M 2.67%34.61M -0.76%33.36M 0.43%33.94M
Development expenditure 48.50%68.21M 40.46%63.38M 35.06%58.95M 17.92%50M 28.87%45.93M 76.33%45.13M 170.24%43.65M 426.87%42.4M --35.64M --25.59M
Long deferred expense -32.34%3.7M 72.21%4.07M 68.63%4.44M 66.25%4.92M 65.95%5.47M -34.86%2.36M -33.59%2.63M -31.14%2.96M -22.95%3.29M -15.98%3.62M
Deferred tax assets 82.38%11.95M 44.44%9.44M 19.95%8.25M -1.84%8.57M -18.71%6.55M -31.38%6.53M -36.22%6.88M -28.18%8.73M -23.88%8.06M 9.45%9.52M
Other non current assets -37.91%24.4M -22.82%32.45M -36.07%26.3M -6.87%29.89M 0.78%39.29M -61.56%42.04M -64.20%41.14M -49.37%32.09M 25.17%38.99M 325.00%109.37M
Total non current assets 3.39%1.48B 6.44%1.47B 8.46%1.47B 11.88%1.46B 6.76%1.43B 7.71%1.39B 15.63%1.36B 31.34%1.31B 50.69%1.34B 67.12%1.29B
Total assets 6.29%3.42B 13.89%3.51B 8.89%3.37B 10.91%3.35B 7.08%3.22B 6.28%3.09B 8.28%3.1B 8.73%3.02B 9.60%3B 12.50%2.9B
Liabilities
Current liabilities
Short term loan -3.97%125.89M 60.45%210.32M 29.23%161.09M 71.85%180.95M -7.03%131.1M 8.92%131.08M 149.05%124.65M 425.87%105.29M --141.01M --120.34M
Notes payable and accounts payable 4.18%163.73M 11.29%188.48M 5.26%174.9M 15.35%180.94M -9.27%157.16M -7.02%169.36M -20.66%166.16M -23.08%156.86M -21.93%173.22M 16.88%182.14M
-Notes payable 6.54%39.8M -12.39%46.58M 1.03%43.68M 398.21%45.8M 19.20%37.35M 85.70%53.17M 8.71%43.24M -79.99%9.19M -39.83%31.34M -29.20%28.63M
-Accounts payable 3.45%123.94M 22.12%141.9M 6.75%131.21M -8.48%135.14M -15.56%119.81M -24.31%116.19M -27.55%122.92M -6.52%147.67M -16.44%141.88M 33.03%153.51M
Contract liabilities 27.51%36.21M 96.50%35.02M 111.24%44.22M 11.40%31.98M 15.63%28.4M -1.77%17.82M 29.22%20.93M 161.15%28.71M 132.65%24.56M 128.34%18.15M
Salaries payable 1.80%38.22M -8.69%32.34M -34.80%26.72M -9.92%49.97M -17.68%37.54M 3.26%35.42M 46.65%40.99M 26.70%55.47M 4.39%45.61M 18.69%34.3M
Taxs payable 56.03%34.89M 87.14%31.34M 63.12%22.71M 7.86%15.87M -0.16%22.36M -15.00%16.74M -15.58%13.92M -12.28%14.71M 1.65%22.4M 22.82%19.7M
Other payable (including interest and dividends) 39.57%247.15M 63.23%262.46M 29.95%225.84M 21.20%195.94M 15.50%177.08M 14.55%160.79M 22.72%173.8M 22.83%161.67M 9.38%153.31M 2.67%140.37M
-Dividend payable ---- --29.63M ---- ---- ---- ---- ---- ---- ---- ----
-Other payable ---- 44.81%232.83M ---- 21.20%195.94M ---- 14.55%160.79M ---- 22.83%161.67M ---- 2.67%140.37M
Non current liabilities due within one year --2.93M --2.93M --2.93M --2.93M ---- ---- ---- ---- ---- ----
Other current liabilities 228.27%13.55M 81.13%4.64M 45.05%8.25M -62.31%2.51M 6.64%4.13M -57.03%2.56M 81.46%5.69M 24.67%6.67M 29.34%3.87M -3.96%5.96M
Total current liabilities 18.79%662.57M 43.79%767.53M 22.07%666.67M 24.88%661.09M -1.10%557.77M 2.46%533.77M 17.48%546.13M 22.41%529.39M 27.79%563.97M 48.15%520.96M
Current liabilities
Deferred tax liabilities 42.11%2.62M 93.15%2.41M 74.83%1.79M 65.06%1.46M 32.95%1.84M -12.12%1.25M 46.83%1.02M 665.62%882.64K 41.99%1.39M 19.85%1.42M
Long term deferred income -6.91%37.85M -4.44%39M -12.33%40.16M -3.80%41.18M -8.78%40.66M -13.80%40.81M -9.09%45.82M -16.10%42.81M -13.61%44.57M -6.01%47.34M
Total non current liabilities -9.14%78.63M 89.13%79.54M 74.19%81.59M 88.22%82.24M 88.28%86.54M -13.75%42.05M -8.33%46.84M -14.57%43.69M -12.57%45.96M -5.41%48.76M
Total liabilities 15.04%741.2M 47.10%847.07M 26.19%748.26M 29.71%743.33M 5.64%644.31M 1.07%575.82M 14.93%592.97M 18.50%573.08M 23.50%609.93M 41.30%569.71M
Shareholders equity
Paid-in capital 47.00%176.53M 47.00%176.53M 0.00%120.09M 0.00%120.09M 0.00%120.09M 0.00%120.09M 0.00%120.09M 0.00%120.09M 0.00%120.09M 0.00%120.09M
Capital reserve funds -4.39%1.38B -4.98%1.37B 0.02%1.44B 0.02%1.44B 0.00%1.44B 0.00%1.44B 0.00%1.44B 0.00%1.44B 0.00%1.44B 0.00%1.44B
Surplus reserve funds 0.00%60.05M 0.00%60.05M 0.00%60.05M 0.00%60.05M 0.00%60.05M 0.00%60.05M 0.00%60.05M 0.00%60.05M 32.25%60.05M 32.25%60.05M
Retained profit 19.04%1.13B 19.43%1.06B 19.67%1.05B 19.42%979.58M 23.07%946.72M 24.87%884.53M 22.19%881.25M 22.90%820.26M 21.01%769.23M 24.94%708.37M
Less:Treasury stock 13,104.68%69.45M --4.58K --54.31M --1.59M --525.95K ---- ---- ---- ---- ----
Specific reserves 74.13%2.23M 113.35%1.92M 281.54%1.39M 5,799.71%989.86K 939.12%1.28M -4.00%898.71K -18.03%363.5K -76.81%16.78K -89.37%123.45K 9.69%936.14K
Shareholders equity without minority interests 4.10%2.68B 6.27%2.67B 4.80%2.63B 6.50%2.6B 7.44%2.57B 7.55%2.51B 6.82%2.51B 6.67%2.44B 6.55%2.39B 7.17%2.33B
Total shareholder equity 4.10%2.68B 6.27%2.67B 4.80%2.63B 6.50%2.6B 7.44%2.57B 7.55%2.51B 6.82%2.51B 6.67%2.44B 6.55%2.39B 7.17%2.33B
Total liabilityies and equity 6.29%3.42B 13.89%3.51B 8.89%3.37B 10.91%3.35B 7.08%3.22B 6.28%3.09B 8.28%3.1B 8.73%3.02B 9.60%3B 12.50%2.9B
Currency Unit CNY CNY CNY CNY CNY CNY CNY CNY CNY CNY
Accounting Standards CAS (2007) CAS (2007) CAS (2007) CAS (2007) CAS (2007) CAS (2007) CAS (2007) CAS (2007) CAS (2007) CAS (2007)
Audit Opinions -- -- -- Unqualified opinion -- -- -- Unqualified opinion -- --
Auditor -- -- -- Zhonghui Certified Public Accountants (Special General Partnership) -- -- -- Zhonghui Certified Public Accountants (Special General Partnership) -- --

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List
CN
Overall
Symbol
Price
% Chg

No Data

Investment Theme Monoclonal Antibody Concept
Monoclonal Antibody Concept
Intraday-0.75%
Innovative Drugs
Innovative Drugs
Intraday-1.01%
Biomedical
Biomedical
Intraday-1.08%